Scientists may have identified a way to naturally regulate blood sugar levels and sugar cravings in a similar fashion to ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

SAN FRANCISCO ― Hanmi Pharmaceutical is poised to bring a new chapter to obesity treatment, a topic that has garnered ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to ...

The mechanism behind semaglutide’s weight loss capabilities ... compared to oral tablets that must be digested. This quick action allows users to experience the benefits of semaglutide without ...

Unlike FDA-approved weight loss medications such as semaglutide and tirzepatide ... rigorous clinical trials and have proven mechanisms of action, typically working by reducing appetite and ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Detailed price information for Biomea Fusion Inc (BMEA-Q) from The Globe and Mail including charting and trades.